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How the MDGs gave up on measuring access to medicines
In March, 2016, the United Nations Statistics 
Commission agreed upon the metrics used to measure 
progress towards, or away from, the new Sustainable 
Development Goals (SDGs).1 These so-called indicators 
deﬁ ne the real-world, measurable counterparts to the 
targets within the visionary goals of the sustainable 
development agenda. In the context of health in the 
SDGs, we wish to highlight the little-known story of 
the Millennium Development Goals’ (MDG) target on 
access to medicines. Of the 21 targets in the eight MDGs 
that permeated the development debate over the past 
15 years, it was the only target that was dropped from 
the MDG report. The lessons learnt from this exclusion 
have important implications for the design of workable 
indicators for the SDGs, and even more importantly, for 
their implementation.
MDG 8 was to “develop a global partnership for 
development”. But the targets of MDG 8 were unique in 
having no time limit, focusing on “actions to be taken 
[primarily] by rich countries”, and being “purposefully 
vague” due to “grossly unequal power relations [...] 
during the negotiations”.2
Access to aﬀ ordable medicines was included in MDG 8 at 
a time when the crisis in access to HIV/AIDS medicines laid 
bare a globally dysfunctional system of pharmaceutical 
pricing.3 This was target 8E: “In cooperation with 
pharmaceutical companies, provide access to aﬀ ordable 
essential drugs in developing countries.”
While target 8E was reported on in the separate MDG 
Gap Task Force reports,4 the target was omitted from the 
last six MDG progress reports, which go straight from 8D 
to 8F (2009–14). The MDG reports do not acknowledge 
or explain the reason for this exclusion.5 Target 8E was 
relegated to a grey zone, reported in some places, and 
not others: some UN sites list “zero” data available for 
the target.6 Although other indicators were neglected 
in this way (eg, within Goal 7), 8E was the only target 
with this fate. After we began making inquiries into 
8E’s absence, it resurfaced after 6 years of absence in the 
2015 MDG report, as a single paragraph acknowledging 
the paucity of data.7 
Data for access to aﬀ ordable medicines is notably 
lacking in comparison to other MDG targets. For 
aﬀ ordability and availability of medicines, the MDG 
Gap Task Force reports averages from a sample of only 
26 country surveys over 7 years (2015). By contrast, 
data for Goal 6 indicators are generally available for 
more than 100 countries.8 These observations suggest 
to us that data collection and reporting for the indicator 
received less priority than other targets. 
The decision to deprioritise 8E is not easy to 
trace. A 2005 Report of the Friends of the Chair 
recommended that target 8E be amended, deleted, 
or have “special eﬀ ort [...] put into setting up 
data collections to provide the information”.9 The 
report recommended that “established” indicators 
that are “closely related to existing data collection 
programmes” should be favoured. Although we could 
not ﬁ nd an explicit record of a decision to abandon 
target 8E, a senior employee in the UN Statistics 
Division explained by email that “[t]he decision not to 
report on the indicator for target 8E was made by the 
WHO representatives in the IAEG [Inter-Agency and 
Expert Group] group [...] A few years ago they decided 
to focus on HIV/AIDS treatment and stopped reporting 
on the rest.” It is concerning to ﬁ nd that a decision like 
this can be made in obscurity without consultation of 
relevant stakeholders.
A substantial part of the value of setting goals, 
targets, and indicators lies in the imperative to collect 
information for measurement and accountability 
—“what gets measured gets done”.10 The decision 
to exclude an indicator because it is less established 
is diametrically opposed to the potential gains of 
establishing new data collection systems. Indicators 
analogous to the MDGs’ indicator on access to 
aﬀ ordable medicines have been proposed as SDG 
indicators.11 
Global goals have substantial inﬂ uence on the agendas 
of governments and NGOs.2 The deprioritisation of 
reporting on access to aﬀ ordable medicines without 
consultation and without broader acknowledgment is 
unacceptable, and undermines global recognition of 
inequalities in access. Without true accountability and 
transparency, the development process is superﬁ cial and 
will fail to engage decision makers. To be taken seriously, 
the SDG targets and indicators on access to aﬀ ordable 
medicines, vaccines, and medical technologies demand 
suﬃ  cient political will and investment for robust 
measurement. 
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